Tampilkan postingan dengan label Center for Public Integrity. Tampilkan semua postingan
Tampilkan postingan dengan label Center for Public Integrity. Tampilkan semua postingan

Kamis, 20 Oktober 2016

  Menu for states seeking lower drug prices

Menu for states seeking lower drug prices


Today’s Managing Health Care Costs Number is 11


The National Academy for State Health Policy published a white paper with 11 initiatives states could use to control health care costs.    I saw this referenced in Pharmalot(part of Stat News) – NASHP is not an organization I had been following.

The national government is responsible for controlling pharmaceutical spending in other developed countries, but the federal government in the US has been unable to effectively address the problem.   But it’s inefficient to ask 51 states to do this work.  Frankly it’s much easier for Big Pharma to do regulatory capture on a state by state basis.   See this Center for Public Integrity article about insurance company state lobbying from last month.

Here’s my take on these 11 concepts:

Concept
Positive Elements
Challenges
1. Increase drug pricing transparency (including requiring disclosure of development costs, rebates, and justification of price increases
This could embarrass the pharmaceutical companies into choosing lower price points.

Anything that makes rebates and discounts less obscure could help!
This encourages misleading accounting – and do we really want drugs to be priced based on the cost of manufacture- or based on “value?”
2. Oversee pharma as a public utility
Pharma has patents that offer a monopoly –so it stands to reason that government should regulate and control prices
Would likely violate the interstate commerce clause. This is a federal issue
3. Bulk prices for public health drugs (immunizations, narcan, hepatitis C drugs)
This works for vaccines already – and is a genuinely good idea
Costs real $$ - so a challenge to fund.
4. Use consumer protection laws (including prohibiting predatory pricing and enforcing antitrust laws)
Antitrust laws could certainly help
Seems like more of a role for the feds
5. Reimport drugs from Canada
They are safe and less expensive
Canada should have lower prices since they have lower GDP AND they have price regulations.  If we reimport a lot from them, their prices will go up or their supplies will shrivel
6. Reform Medicaid
Medicaid could get lower prices if it could exclude drugs, and the current mandatory rebates likely raise overall costs
The proposal suggests extending the rebates to exchange plans
7. States become PBMs or create purchasing pools
This could disintermediate the middle men
PBMs have built their business and business model over decades.  Pharmaceutical companies might be reluctant to deal with new market entrants, and they could fail
8. Pursue value pricing
Pay what a drug is really worth (including health benefits and productivity and other benefits).  Consider paying only when the benefit occurs (e.g. liver transplant prevented by Harvoni)
Difficult to pursue unless the Medicaid guaranteed rebates are stopped – and most drugs (except vaccines and birth control) save lives for a reasonable price – they don’t save money
9. Use Employer Group Waiver Plans (EGWP) for retirees
The federal government pays a portion of drug costs
Many states already do this – and it’s just a cost shift.
10. Protect consumers from misleading marketing
Would be great to get rid of these drug coupons that help sustain high list prices
The only state that did this (MA) discontinued ban in 2012.
11. Shareholder activism
States should use their $3.8 trillion pension fund to advocate for better pharma behavior
Shareholder activism rarely drives business change – and this could lower pension plan yields.

All in, this is an interesting group of suggestions.   States purchase a lot of medications themselves on behalf of state and local government employees, retirees, and to serve public heath needs.  They can positively influence the pharmaceutical market through aggressive purchasing.   It’s likely that this will be through pharmacy benefit managers for now, though – as setting up an alternative approach would be costly, time-consuming, and have uncertain benefits.

Rabu, 21 September 2016

Pharma spent $880 million lobbying to prevent opioid regulations over 10 years

Pharma spent $880 million lobbying to prevent opioid regulations over 10 years

Today's Managing Health Care Costs Number is $880 million


The Associated Press and the Center for Public Integrityreported on pharmaceutical company lobbying at the state level earlier this week;  this was to look specifically at lobbying around opiod regulation.  Pharma spent $880 million over a decade - while the anti-opioid lobby spent about $4 million.   The industry and allied groups have an "army of lobbyists averaging 1,350 per year covering all 50 state capitals."  The report says that the opioid lobby spent eight times as much as the gun lobby for political activities over the last decade.

This matters. While the attention of the national press is on Congress and the Food and Drug Administration, most laws around prescription practice are enacted on the state level. The level of scrutiny for state governmental action is low.  Few Americans know who their state legislators are -never mind whether they have voted for bills that promote excessive use of dangerous, addictive medications.   One percent of local news coverage is about the state legislature.

Many state legislatures pass bills that are written by lobbyists, and pharmaceutical companies have funded "astroturf" groups like the Pain Care Forum to promote their interests, and there is even a division of the American Cancer Society (the Cancer Action Network) which has lobbied against opioid legislation in 18 states.  States determine what rules pharmacies and prescribing clinicians must follow - and as of earlier this year only 16 states had mandatory prescription drug monitoring databases for physicians to use to prevent doctor shopping for narcotics.

We need more attention to state legislative and regulatory processes -and this reporting is a good start.  Pharma doesn't always win - the AP report includes a sidebaron a pharma company failure to stop opioid regulations in Washington State.